Repeated Stereotactic Radiosurgery for Patients with Progressive Brain Metastases

Overview

Journal J Neurooncol

Publisher Springer

Date 2015 Sep 16

PMID 26369769

Citations 38

Authors

Giuseppe Minniti

Claudia Scaringi

Sergio Paolini

Enrico Clarke

Francesco Cicone

Vincenzo Esposito

Andrea Romano

Mattia Osti

Riccardo Maurizi Enrici

Affiliations

Soon will be listed here.

Abstract

In the present study we have evaluated the efficacy and toxicity of repeated stereotactic radiosurgery (SRS) in patients with recurrent/progressive brain metastases. Between March 2006 and October 2014, 43 patients (21 men and 22 women) with 47 lesions received a second course of SRS given in three daily fractions of 7-8 Gy. With a follow-up study of 19 months, the 1- and 2-year survival rates from repeated SRS were 37 and 20%, respectively, and the 1- and 2-year local control rates were 70 and 60%, respectively. Actuarial local control was significantly better for breast and lung metastases as compared with melanoma metastases; specifically, 1-year local control rates were 38% for melanoma, 78% for breast carcinoma and 73% for non-small cell lung cancer (NSCLC) metastases (p = 0.01). The cause of death was progressive systemic disease in 25 patients and progressive brain disease in 11 patients. Stable extracranial disease (p = 0.01) and Karnofsky performance status (KPS; p = 0.03) were predictive of longer survival. Radiologic changes suggestive of brain radionecrosis were observed in 9 (19%) out of 47 lesions, with an actuarial risk of 34% at 12 months. Neurological deficits (RTOG Grade 2 or 3) associated with brain necrosis occurred in 14% of patients. In conclusion, a second course of SRS given in three daily fractions is a feasible treatment for selected patients with recurrent/progressive brain metastases. Further studies are needed to explore the efficacy and safety of different dose-fractionation schedules, especially in patients with melanoma or large metastases.

Citing Articles

Outcomes of Management of Progressive Radiosurgery-Treated Brain Metastasis With Resection Followed by Pathology-Informed Management: A Retrospective Study.

Bhatia R, George J, Siu C, Lee E, Redmond K, Baker B Neurosurg Pract. 2025; 5(4):e00117.

PMID: 39959539 PMC: 11809956. DOI: 10.1227/neuprac.0000000000000117.

Multidisciplinary management strategies for recurrent brain metastasis after prior radiotherapy: An overview.

Kotecha R, La Rosa A, Brown P, Vogelbaum M, Navarria P, Bodensohn R Neuro Oncol. 2024; 27(3):597-615.

PMID: 39495010 PMC: 11889725. DOI: 10.1093/neuonc/noae220.

Stereotactic Radiosurgery for Intracranial Breast Metastases: A Systematic Review and Meta-Analysis.

Almeida N, Kuo C, Schrand T, Rupp J, Madhugiri V, Goulenko V Cancers (Basel). 2024; 16(20).

PMID: 39456645 PMC: 11506708. DOI: 10.3390/cancers16203551.

Repeated HyperArc radiosurgery for recurrent intracranial metastases and dosimetric analysis of recurrence pattern to account for diffuse dose effect on microscopical disease.

Nicosia L, Allegra A, Giaj-Levra N, Bayani R, Darzikolaee N, Mazzola R Clin Transl Radiat Oncol. 2024; 48:100811.

PMID: 39036468 PMC: 11260387. DOI: 10.1016/j.ctro.2024.100811.

Factors associated with the local control of brain metastases: a systematic search and machine learning application.

Kanakarajan H, De Baene W, Gehring K, Eekers D, Hanssens P, Sitskoorn M BMC Med Inform Decis Mak. 2024; 24(1):177.

PMID: 38907265 PMC: 11191176. DOI: 10.1186/s12911-024-02579-z.

References

Blonigen B, Steinmetz R, Levin L, Lamba M, Warnick R, Breneman J . Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 2009; 77(4):996-1001. DOI: 10.1016/j.ijrobp.2009.06.006. View

Dummer R, Goldinger S, Turtschi C, Eggmann N, Michielin O, Mitchell L . Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer. 2013; 50(3):611-21. DOI: 10.1016/j.ejca.2013.11.002. View

Akyurek S, Chang E, Mahajan A, Hassenbusch S, Allen P, Mathews L . Stereotactic radiosurgical treatment of cerebral metastases arising from breast cancer. Am J Clin Oncol. 2007; 30(3):310-4. DOI: 10.1097/01.coc.0000258365.50975.f6. View

Hoffman R, Sneed P, McDermott M, Chang S, Lamborn K, Park E . Radiosurgery for brain metastases from primary lung carcinoma. Cancer J. 2001; 7(2):121-31. View

Vecil G, Suki D, Maldaun M, Lang F, Sawaya R . Resection of brain metastases previously treated with stereotactic radiosurgery. J Neurosurg. 2005; 102(2):209-15. DOI: 10.3171/jns.2005.102.2.0209. View

Yang H, Kano H, Lunsford L, Niranjan A, Flickinger J, Kondziolka D . What factors predict the response of larger brain metastases to radiosurgery?. Neurosurgery. 2011; 68(3):682-90. DOI: 10.1227/NEU.0b013e318207a58b. View

Aoyama H, Shirato H, Onimaru R, Kagei K, Ikeda J, Ishii N . Hypofractionated stereotactic radiotherapy alone without whole-brain irradiation for patients with solitary and oligo brain metastasis using noninvasive fixation of the skull. Int J Radiat Oncol Biol Phys. 2003; 56(3):793-800. DOI: 10.1016/s0360-3016(03)00014-2. View

Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K . Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006; 295(21):2483-91. DOI: 10.1001/jama.295.21.2483. View

Voges J, Treuer H, Sturm V, Buchner C, Lehrke R, Kocher M . Risk analysis of linear accelerator radiosurgery. Int J Radiat Oncol Biol Phys. 1996; 36(5):1055-63. DOI: 10.1016/s0360-3016(96)00422-1. View

10.

Chang E, Wefel J, Hess K, Allen P, Lang F, Kornguth D . Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009; 10(11):1037-44. DOI: 10.1016/S1470-2045(09)70263-3. View

11.

Selek U, Chang E, Hassenbusch 3rd S, Shiu A, Lang F, Allen P . Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys. 2004; 59(4):1097-106. DOI: 10.1016/j.ijrobp.2003.12.037. View

12.

Minniti G, DAngelillo R, Scaringi C, Trodella L, Clarke E, Matteucci P . Fractionated stereotactic radiosurgery for patients with brain metastases. J Neurooncol. 2014; 117(2):295-301. DOI: 10.1007/s11060-014-1388-3. View

13.

Ernst-Stecken A, Ganslandt O, Lambrecht U, Sauer R, Grabenbauer G . Phase II trial of hypofractionated stereotactic radiotherapy for brain metastases: results and toxicity. Radiother Oncol. 2006; 81(1):18-24. DOI: 10.1016/j.radonc.2006.08.024. View

14.

Minniti G, Clarke E, Lanzetta G, Osti M, Trasimeni G, Bozzao A . Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol. 2011; 6:48. PMC: 3108308. DOI: 10.1186/1748-717X-6-48. View

15.

Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J . Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys. 2000; 47(2):291-8. DOI: 10.1016/s0360-3016(99)00507-6. View

16.

Fahrig A, Ganslandt O, Lambrecht U, Grabenbauer G, Kleinert G, Sauer R . Hypofractionated stereotactic radiotherapy for brain metastases--results from three different dose concepts. Strahlenther Onkol. 2007; 183(11):625-30. DOI: 10.1007/s00066-007-1714-1. View

17.

Cicone F, Minniti G, Romano A, Papa A, Scaringi C, Tavanti F . Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery. Eur J Nucl Med Mol Imaging. 2014; 42(1):103-11. DOI: 10.1007/s00259-014-2886-4. View

18.

Sneed P, Suh J, Goetsch S, Sanghavi S, Chappell R, Buatti J . A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys. 2002; 53(3):519-26. DOI: 10.1016/s0360-3016(02)02770-0. View

19.

Chen J, Petrovich Z, Giannotta S, Yu C, Apuzzo M . Radiosurgical salvage therapy for patients presenting with recurrence of metastatic disease to the brain. Neurosurgery. 2000; 46(4):860-6; discussion 866-7. DOI: 10.1097/00006123-200004000-00017. View

20.

Nedzi L, Kooy H, Alexander 3rd E, Gelman R, Loeffler J . Variables associated with the development of complications from radiosurgery of intracranial tumors. Int J Radiat Oncol Biol Phys. 1991; 21(3):591-9. DOI: 10.1016/0360-3016(91)90675-t. View